Virpax Pharmaceuticals to Present at 2024 BIO International Convention

Virpax Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)

BusinesswireMay 29 06:30

Maxim Group Downgrades Virpax Pharmaceuticals(VRPX.US) to Hold Rating

Maxim Group analyst Naz Rahman downgrades $Virpax Pharmaceuticals(VRPX.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 29.7% and a total average return of -11.5% ov

Futu NewsMay 23 05:32

Maxim Group: Downgraded Virpax Pharmaceuticals (VRPX.US) rating from buy to hold

Maxim Group: Downgraded Virpax Pharmaceuticals (VRPX.US) rating from buy to hold

Zhitong FinanceMay 22 10:50

Maxim Group Downgrades Virpax Pharmaceuticals to Hold

Maxim Group analyst Naz Rahman downgrades Virpax Pharmaceuticals from Buy to Hold.

Analyst UpgradesMay 22 10:46

Virpax Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 — Maxim Group Downgrades Buy → Hold 06/09/2022 471.43% Maxim Group → $4 Initiates Coverage On

BenzingaMay 22 10:45

SINTX Technologies SINT Earnings; Virpax Pharmaceuticals VRPX Earnings

BioPharmCatalystMay 15 14:46